Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
(Q83145997)
scientific article published on 27 December 2011
scientific article published on 27 December 2011
Language:
other details
| description | scientific article published on 27 December 2011 |
External Links
| (P356) |
10.1200/JCO.2011.36.9215
|
| (P698) |
22203755
|